Stassets Investment
VC Fund
Seoul, South Korea
Stassets Investment is a VC fund in Seoul focused on Health Care and Medical. Stassets Investment focuses on the healthcare sector and specializes in early stage investments.
- Total investments:
- 11
- Last investment:
- Lead investor:
- 36%
Last updated:
For AI agents: llms.txt
Industries Stassets Investment invests in
Stages Stassets Investment invests in
Countries Stassets Investment invests in
Investment Focus
Industry
- Health Care 5 (45%)
- Medical 4 (36%)
- Biotechnology 3 (27%)
- Therapeutics 2 (18%)
- Pharmaceutical 2 (18%)
Stage
- Series A 5 (45%)
- Series B 4 (36%)
- Series C 1 (9%)
- Post-IPO Equity 1 (9%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
PROMEDIUS
|
Promedius is a MedTech startup, based in Seoul, Korea, focusing on optimizing radiologists workflow of medical imaging interpretation to drive improved patient outcomes. Our platform, AIdant, is providing an AI-enabled medical imaging cloud solution for individual doctors, medical institutions, and teleradiology centers. We believe ourcomprehensive zero-footprint AI solution can cover the geographic issues, after-hour issues, and lack of the radiologists issue in the diagnostic imaging market. | $14M / Series B / Jun 05, 2026 | |
Orum Therapeutics
|
Orum Therapeutics is a private biotech company developing a new class of therapeutic antibodies targeting cytosolic proteins for unmet medical needs in cancer and rare diseases. Orum leverages its unique cell-penetrating antibody platform, called Oromab™ to inhibit drug targets, previously undruggable by small molecules or current antibodytherapeutics. In contrast to other approaches, Orum’s antibody platform can intracellularly deliver an active antibody therapeutic or payload, is easily adaptable to target different cell types and intracellular proteins, and does not require chemical modification. | $98.3M / Post-IPO Equity / Dec 18, 2025 | |
Nobo Medicine
|
Nobo Medicine is a clinical-stage biotech company focused on developing precision therapies for blood cancers and immune-related aging diseases. It uses biomarker-driven drug discovery and translational research to identify targeted treatments, aiming to improve outcomes in oncology and age-associated immune dysfunction through innovative,data-driven biomedical approaches. | $19.8M / Series C / Jul 28, 2025 | |
Avelos Therapeutics
|
Avelos Therapeutics is a precision medicine company in the clinical stage that finds, creates, and sells targeted therapeutics. | $12.4M / Series B / May 02, 2024 | |
Algocare
|
Algocare is a AI based healthcare startup that offers specialised Nutrition as a Service (NaaS) to people and organisations. | $11.3M / Series A / Mar 14, 2024 | |
|
PROMEDIUS
|
Promedius is a MedTech startup, based in Seoul, Korea, focusing on optimizing radiologists workflow of medical imaging interpretation to drive improved patient outcomes. Our platform, AIdant, is providing an AI-enabled medical imaging cloud solution for individual doctors, medical institutions, and teleradiology centers. We believe ourcomprehensive zero-footprint AI solution can cover the geographic issues, after-hour issues, and lack of the radiologists issue in the diagnostic imaging market. | $8.5M / Series A / Mar 08, 2024 | |
Grade Health Chain
|
Grade Health Chain is a fintech company that develops insurance products which allows for premium discounts by collecting and analyzing health data. The platform developed by the company assesses the health grade based on the results of health checkups and provides an intuitive display of the user's health status. This allows users to receivevarious benefits based on their efforts to improve their health. | $4.5M / Series B / Mar 07, 2024 | |
Dencom
|
Dencom is an IT company that creates dental platforms for medical services. | $7.5M / Series A / Feb 22, 2024 | |
Vetching
|
Vetching started with the meaning of matching veterinarians and veterinary hospital customers by combining veterinarian and matching. | $6M / Series A / Aug 28, 2023 | |
C-Biomex
|
C-Biomex is a biotech drug development company that provides diagnostic therapy and radiopharmaceuticals. | $5M / Series B / Jun 22, 2022 | |
| See all 11 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Stassets Investment invest in?
Stassets Investment invests primarily in Health Care, Medical and Biotechnology startups, most often at Series A and Series B stage. Most of the 11 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Stassets Investment last invest?
The most recent investment recorded for Stassets Investment closed in Jun 2026. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
